Paclitaxel in combination with cisplatin is less effective for peripheral blood progenitor cell mobilization

The purpose of this study was to determine the efficacy of paclitaxel in co mbination with cisplatin and granulocyte-colony stimulating factor (G-CSF) for mobilization of peripheral blood progenitor cells (PBPC). Twenty-seven patients with gynecological cancer received paclitaxel and cisplatin (TP, n = 9) or other platinum-based chemotherapy (n = 18) (etoposide and cisplati n [n = 5]; cyclophosphamide, adriamycin, and cisplatin [n = 8]; or pepleomy cin, etoposide, and cysplatin [n = 5]). Each combination was followed by G- CSF. The mean number of colony-forming unit granulocyte macrophage (CFU-GM) /kg and CD34(+) cells/kg collected per cycle was 1.2 x 10(5) ind 0.8 x 10(6 ) after the TP regimen, compared with 2.6 x 10(5) (P < 0.05) and 2.0 x 10(6 ) for patients who received other platinum-based chemotherapy. The CFU-GM t arget yield (<greater than or equal to>1.0 x 10(5)/kg) was achieved in 56% and 83% patients in the TP and comparison group, respectively. With the TP regimen, a younger age (less than or equal to 50 years of age) and fewer pr ior chemotherapy cycles (less than or equal to2) were associated with the C FU-CM targeted yield (<0.05). In conclusion, TP mobilized PBPC less effecti vely than other platinum-based chemotherapy. Therefore, the TP regimen may need to be changed to another appropriate regimen when PBPC mobilization is planned for high-dose chemotherapy in gynecological cancer patients.